This is an old revision of the document!
Alexander Doroshenko
Dr. Alexander Doroshenko is an infectious disease epidemiologist and public health specialist in Alberta, Canada. His interests include evaluation of public health interventions and evidence-base public health policies.
Affiliations
Alberta Health Services
Doroshenko is the Public Health representative for the COVID-19 Scientific Advisory Group under Alberta Health Services.1)
University of Alberta
Doroshenko is an Assistant Professor in the Department of Medicine, Faculty of Medicine and Dentistry at the University of Alberta.2)
Publications
- Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review 3)
- Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines)4)
- Co-authored with Scott Halperin, who has an extensive catalogue of vaccine-related publications and was funded by Novartis for this study
- In collaboration with the Canadian Center for Vaccinology
- What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model5)
- Funded by Alberta Health Services and the University of Alberta
- Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures: Alberta, Canada6)
- Doroshenko reported receiving personal fees from Sanofi for an advisory role
- He also reported that his employer, the University of Alberta, was paid additional funds in research grants from the Canadian Institutes of Health Research (CIHR), Public Health Agency of Canada, Alberta Health Services, and the University of Alberta Hospital Foundation.
- The study found that the public health measures Doroshenko helped put in place were “associated with a substantial reduction in influenza and NIRV infections in Alberta.”
1)
2019-nCoV Scientific Advisory Group. (2021, May 27). Alberta Health Services. https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-terms-of-reference.pdf
2)
Alexander Doroshenko | Public Health. University of Alberta. Retrieved January 8, 2022, from https://www.ualberta.ca/public-health/about/faculty-staff/adjunct-emeritus-faculty/doroshenko.html
3)
Somerville, M., Curran, J. A., Dol, J., Boulos, L., Saxinger, L., Doroshenko, A., Hastings, S., Reynolds, B., Gallant, A. J., Shin, H. D., Wong, H., Crowther, D., Macdonald, M., Martin-Misener, R., Comeau, J., McCulloch, H., & Tricco, A. C. (2021). Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review. BMJ Open, 11(12), e055781. https://doi.org/10.1136/bmjopen-2021-055781
4)
Doroshenko, A., & Halperin, S. A. (2009). Trivalent MDCK cell culture-derived influenza vaccine Optaflu®(Novartis Vaccines). Expert Review of Vaccines, 8(6), 679–688. https://doi.org/10.1586/erv.09.31
5)
Rafferty, E. R. S., McDonald, W., Osgood, N. D., Doroshenko, A., & Farag, M. (2021). What We Know Now: An Economic Evaluation of Chickenpox Vaccination and Dose Timing Using an Agent-Based Model. Value in Health, 24(1), 50–60. https://doi.org/10.1016/j.jval.2020.10.004
6)
Doroshenko, A., Lee, N., MacDonald, C., Zelyas, N., Asadi, L., & Kanji, J. N. (2021). Decline of Influenza and Respiratory Viruses With COVID-19 Public Health Measures. Mayo Clinic Proceedings, 96(12), 3042–3052. https://doi.org/10.1016/j.mayocp.2021.09.004